Long-acting technologies
31 articles
Call for New Global Long-Acting Technologies CAB Members from Asian, Central African, Eastern European, MENA, and Latin American Countries
TAG and AfroCAB announce an expanded call for a new cross-disease LAT CAB focused on malaria, hepatitis C, and latent TB. Apply now! Applications accepted on a rolling basis. More
Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments
A survey sought to understand the acceptability of approaches to long-acting HCV treatment. More
World Malaria Day 2022 LAT CAB Statement
In reflection of World Malaria Day, LAT CAB issues a statement calling for a multi-pronged malaria eradication approach. More
Long-Acting Technologies Trials Tracker for Hepatitis C, Opioid Use and Overdose Prevention Therapy, and Malaria
TAG released a trials tracker providing information on the development of long-acting HCV, malaria, and opioid use and overdose prevention therapy formulations. More
LAT CAB Video Presentation
In a video, LAT CAB members describe the goal of the CAB, and how long-acting therapies for malaria, latent TB prevention and HCV cure will benefit affected communities. More
